EP4188389
Dapaglíflosín til notkunar í aðferðum til meðhöndlunar á langvinnum nýrnasjúkdómi
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
1.4.2021EP published:
17.9.2025EP application number:
21716724.6
EP translation filed:
26.11.2025Grant published:
15.12.2025EPO information:
European Patent Register
Max expiry date:
31.3.2041Expiry date:
31.3.2026
Title in English:
DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASELanguage of the patent:
English
Timeline
Today
1.4.2021EP application
17.9.2025EP Publication
26.11.2025Translation submitted
15.12.2025Registration published
31.3.2026Expires
Owner
Name:
AstraZeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
LANGKILDE, Anna MariaAddress:
151 85 Södertälje, SE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202063057139 PDate:
27.7.2020Country:
US
Number:
202063070869 PDate:
27.8.2020Country:
US
Number:
202063082524 PDate:
24.9.2020Country:
US
Number:
202063093961 PDate:
20.10.2020Country:
US
Number:
202063119711 PDate:
1.12.2020Country:
US
Number:
202163152445 PDate:
23.2.2021Country:
US
Number:
202163161629 PDate:
16.3.2021Country:
US
Classification
Categories:
A61K 31/70, A61P 31/12